Amrutanjan Health Care growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+11.2%+7.3%+11.0%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+30.0%+13.6%+15.4%
+34.2%+14.4%+15.3%
+13.9%+13.0%+12.9%
+13.9%+13.0%+14.0%
+20.8%+14.9%+1.3%
+13.4%+13.2%−0.8%
−29.3%+82.4%+45.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AMRUTANJAN₹493.20

Amrutanjan Health Care Limited

· Pharma & Health
₹ CrorePeersJAGSNPHARMNGLFINESIGACHILINCOLNSYNCOMFTHEMISMEDHESTERBIOMcap ₹1,426 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+11.0+7.3+11.2—
EBITDA Growth—+15.4+13.6+30.0—
EBIT Growth—+15.3+14.4+34.2—
Net Income Growth—+12.9+13.0+13.9—
EPS Growth—+14.0+13.0+13.9—
Total Assets Growth—+1.3+14.9+20.8—
Total Equity Growth—-0.8+13.2+13.4—
Cash from Operations Growth—+45.2+82.4-29.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.